Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (3702)	9/18/1999 8:10:00 PM
From: pz	Read Replies (1) \| Respond to of 10293

Bill, Refute this. Paul The following abstract was copied with permission from the 5 ISABC Book of Abstracts, 5th International Symposium on Applied Bioinorganic Chemistry, 13-17 April 1999, Corfu, Greece. _____________ THE EFFECT OF DIRECT APPLICATION OF IONIC ZINC NASAL GEL ON THE SEVERITY AND DURATION OF THE COMMON COLD. Charles B. Hensley, Ph.D and R. Steven Davidson, Ph.D Gel Tech Inc. 6430 Variel Ave. S. 102, Woodland Hills, California 91367 U.S.A. Over 200 viruses can cause the common cold with the majority being caused by rhinoviruses. Human rhinovirus (HRV) entry into the nasal epithelium is mediated by binding to a cellular receptor and is a critical first step in the infection process. In the human nasal mucosa, intercellular adhesion molecule (ICAM-1) is known to be the receptor used by HRV to gain entry into the human nasal epithelium. Furthermore, molecular modeling reveals that the ICAM-1 docking sites on the surface of HRV are ideally constituted and disposed to receive zinc ions. These and other observations led us to hypothesize that strategic application of ionized zinc to the nasal epithelium would result in zinc ions occupying these sites, which would prevent HRV docking with ICAM-1, effectively interrupting the HRV infection cycle. To this end, we have developed a common cold therapy based on direct application of ionic zinc to the nasal epithelial surface via a gel matrix delivery system. The aim of this study was to evaluate the effectiveness of our preparation in reducing the severity and duration of the common cold. The double blind, placebo controlled study was conducted over a two cold season period. Two hundred volunteers were initially enrolled in the study of which one hundred and four participated (those presenting with at least three of nine cold symptoms for a period of 24 hours or less). Each subject received a pump sprayer containing either 10 mM zinc nasal gel (n=12), 33 mM zinc nasal gel (n=40), or placebo gel (n=52). Subjects were instructed to spray one dose per nostril every four hours during waking hours and just prior to retiring for the evening for as long as they had cold symptoms. Subjects completed a symptom chart documenting the severity (scale of 0 to 3) of symptoms throughout the duration of their colds. Colds were determined to be over only when all symptoms were resolved (a total symptom score of 0). The 33mM zinc nasal gel was more effective than the other treatment protocols at reducing both the severity and duration of the common cold. We used the Kaplan-Meier method to estimate the percentage of subjects whose colds completely resolved. The mean resolution time for all symptoms was 1.5 +/- 0.82 days (n=40) for subjects using 33 mM zinc gel, 3.29 +/- 1.03 days (n=12) for subjects using 10 mM zinc gel, and 9.8 +/- 4.5 days (n=52) for subjects using the placebo gel. The results of the Student's t Test and the plot of these distributions demonstrate that symptoms resolved significantly faster in the zinc groups than in the placebo group (p < 0.001 for 33 mM zinc; p < 0.001 for 10 mM zinc). The analysis also showed that the cold duration was shorter in the 33 mM zinc group when compared with the 10 mM zinc group (p < 0.005). In conclusion, we find that direct application of ionic zinc to the nasal epithelial surface to be very effective in reducing the severity and duration of the common cold symptoms. The nasal gel containing 33 mM ionized zinc significantly reduced the duration of the common cold from an average of 9.8 days in the placebo group to an average of 1.5 days, which amounts to an 85% reduction in the duration of the common cold.

To: Bill Wexler who wrote (3702)	9/18/1999 10:05:00 PM
From: DanZ	Read Replies (3) \| Respond to of 10293

Bill, If you continue to bash GumTech with unsubstantiated crap, I will continue to post here whether your loyal followers like it or not. I find it ironic that the loyal group directs their "I don't want to hear about GUMM anymore" comments at those who are long, when the only reason that we post here is to address the constant unsubstantiated bullshi* from you and others. Your comment: "The GUMM fraud is simply another outgrowth of the current homeopathy fad." shows ignorance of the labeling issue that has been described to you several times. This comment also shows no regard for the abstract that I posted on the GUMM thread earlier today. Why don't you make some salient comments about the abstract instead of unleashing a barrage of irrelevant comments about other stocks? I think your logic goes like this: I told those people that company A was a fraud and the price of the stock A went down. Therefore, company A IS indeed a fraud and company's B and C are frauds too just because I say they are. Not only do you need a lesson in the interaction between zinc, ICAM-1, and rhinoviruses, but you also need a lesson in Logic 101.